Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).

Sotio Biotech

The mission of SOTIO Biotech, the biotechnology company that joined PPF Group in 2012, is to research, develop, and provide access to new and innovative treatment methods for patients suffering from severe forms of cancer.

SOTIO Biotech is building a diversified portfolio of cancer treatment products based on its own research and development, cooperation with partners, licensing agreements, investments, and mergers and acquisitions. Teams of top Czech and foreign experts work at SOTIO Biotech within the framework of its far-reaching international activities.

SOTIO Biotech has the internal capacities it needs for research, clinical development, and product marketing. SOTIO Biotech’s activities are the largest privately-funded research in the medical field in the Czech Republic. SOTIO Biotech also has operations in Europe, in the US and China.


SOTIO Biotech verifies the safety and efficacy of the products it is developing in a number of phase I to III clinical trials. Since 2012, the company has initiated thirteen clinical studies in Europe and the US focusing on patients with solid tumors, especially those with various types of cancer. 

SOTIO Biotech actively seeks out opportunities to work with other companies and institutions developing promising oncology treatments. In addition, it manages PPF Group’s investments in UK's biotechnology company Autolus Therapeutics and Swiss company Cellestia Biotech.

Other Companies

Cytune Pharma SAS

Cytune Pharma is a French biotechnology company researching and developing new therapies designed to strengthen the immune response of patients suffering from cancer and infectious diseases. It is member of the SOTIO Biotech group, which develops Interleukin-15-based products based on research of Cytune Pharma.

Autolus Therapeutics

Autolus Therapeutics is a leader in the development of treatments based on CAR-T cells (genetically engineered T cells). The company is dedicated to the clinical development of a wide portfolio of next-generation T-cell therapies targeting both hematological and solid tumors.     

Cellestia Biotech

Cellestia Biotech was founded in 2014 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPLF). Cellestia’s lead development compound is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor with an innovative mode of action meant for the treatment of patients with NOTCH-driven lymphomas and solid tumors.

Sotio Biotech

Sale of PPF's Stake in NBE-Therapeutics

At the end of 2020, PPF sold its stake in NBE-Therapeutics, a company developing innovative ADC products for the treatment of solid tumors, to leading global pharmaceutical company Boehringer Ingelheim.

This deal, the largest of its kind in Europe in 10 years, showed the value of the ADCs that SOTIO Biotech maintains in its portfolio and that it continues to develop. These products could reach their first patients in the beginning of 2022 in the first phase of clinical trials.

"SOTIO exemplifies the world-class standard of Czech science in its mission and results. Our efforts are focused on finding a cure for cancer."

Radek Špíšek

CEO, SOTIO Biotech


SOTIO Biotech a.s.

Jankovcova 1518/2
170 00 Praha 7
Czech Republic

PPF Biotech B.V.

Strawinskylaan 933
1077 XX Amsterdam
The Netherlands